No Data
No Data
Sidoti Events, LLC's Virtual June Small-Cap Conference
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day June Small-Cap Conference taking place
HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $4 Price Target
HC Wainwright & Co. analyst Vernon Bernardino reiterates Citius Pharma (NASDAQ:CTXR) with a Buy and maintains $4 price target.
Citius Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 497.82% HC Wainwright & Co. $4 → $4 Reiterates Buy → Buy 02/14/2024 497.82% HC Wainwright & Co.
Buy Rating Reaffirmed for Citius Pharmaceuticals Amid Strong Clinical Trial Results and Growth Prospects
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Analysts Are Bullish on Top Healthcare Stocks: Citius Pharmaceuticals (CTXR), Actinium Pharmaceuticals (ATNM)